NanoSPECT-CT technique provides in vivo
, longitudinal, quantitative and functional images. Imaging approaches also offer ethical advantages by largely reducing the number of animals needed (3-R rule). Blood-brain barrier permeability was studied on day 3 by injecting 20 MBq/100 μL
99mTc-diethylenetriaminepentacetate (DTPA), (Pentacis®, France) into the lateral tail vein.
99mTc-DTPA is a hydrophilic agent that cannot pass through an intact blood-brain barrier.
99mTc-DTPA was previously used to explore blood-brain barrier disruptions in clinical studies and in other rodent models of acute neurological injuries [
29]. On day 4, we evaluated the uptake of
99mTc-Anx-V128 (Atreus Pharmaceuticals®, Ottawa, Canada).
99mTc-Anx-V128 is a novel radiolabelled agent that target the negative phosphatidyl serine exposed on cell membranes. It is used for quantification of apoptosis. Finally, we studied the kinetics of cerebral perfusion by injecting 20 MBq/150 μL
99mTc-hexamethylpropyleneamineoxime (HMPAO) (Cerestab®, GE Healthcare, France).
99mTc-HMPAO, a lipophilic agent that passes through the blood-brain barrier, is metabolized in neurons, and the metabolites are trapped in the brain. This agent is well-validated for exploring cerebral perfusion in animals [
30] and humans [
31]. Since animals remain awake during radiotracer uptake and move freely before imaging, this technique prevents the bias of cerebral blood flow disturbances secondary to anaesthetic exposure.
99mTc-HMPAO NanoSPECT images were acquired at two time points: in the basal state (day 0) and after SAH conditions were established (day 5). Forty minutes after the radiolabelled agent injection, animals were imaged with a nanoSPECT/CTplus® camera (Mediso, Hungary). Before SPECT imaging, we obtained a 0.8-mm-slice thickness CT scan of the encephalic region. During the scan, the animals were anaesthetized with isoflurane (1.5 vol%), and body temperature was maintained. Images were reconstructed and analysed with the 3D-ROI module provided in InVivoScope® software v2.0p4 (InviCRO). After co-registration between SPECT and CT scan acquisitions, three regions of interest (ROI) were drawn, based on anatomical landmarks identified in the CT images. The brainstem ROI was delimited cranially by the spheno-occipital synchondrosis and caudally by the foramen magnum. A frontal plane, passing through the fourth ventricle, delimited the cerebellum and brainstem ROIs in the antero-posterior axis. The transverse cerebral fissure was used to distinguish the cerebellum ROI from the cerebral hemispheres. Radioactivity inside each ROI was quantified and corrected according to the tissue volume (MBq/mm
3), then divided by the total effective injected dose, after correcting for radioactive decay of
99mTc. For each ROI, the radioactivity was expressed in parts per million of the injected dose (ppmID/mm
3). The uptakes of
99mTc HMPAO on day 5 were expressed as the percentage of basal uptake (day 0).